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Abstract
Background: Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is
proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based
on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other
derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These
contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd
contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity
and Gd safety.
Methodology/Principal Findings: To determine whether a biocompatible lipid nanoparticle with surface bound Gd can
improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The
Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater
than 33-fold higher longitudinal (T1) relaxivity, r1, constant than the current FDA approved Gd-chelated contrast agents.
Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise
ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal
vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to
accumulate in the liver or kidney, and was eliminated completely within 24 hrs.
Conclusions/Significance: The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced
dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees
of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug
delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in
treatment of cancers and other diseases.
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Introduction
Magnetic resonance imaging (MRI) plays a pivotal role in non-
invasive visualization and quantification of vascular and tissue
pathology or physiologic processes. The use of paramagnetic
contrast agents increases sensitivity and specificity of medical
diagnoses based on MRI. The paramagnetic MR contrast agents
modify the local magnetic environment due to interactions
between unpaired electrons of contrast media, such as gadolinium
(Gd
3+), and the hydrogen nuclei of water in the blood, tissues and
organs in the body. Among paramagnetic compounds, Gd is the
primary agent used for MRI due to high relaxation efficiency and
magnetic moments. As a free, soluble ionic metal ion, Gd
3+ is
highly toxic, probably due to its affinity for metalloproteins and
calcium binding proteins. Therefore, Gd contrast agents are
formulated as Gd bound chemical chelates that are water soluble
to improve their clinical safety profile. Some of the clinically used
Gd-chelates include DTPA (Magnevist), BOPTA (MultiHance),
HP-DO3A (ProHance), DTPA-BMEA (Optimark), DTPA-BMA
(Omniscan), DOTA (Dotarem), and DTPA-DPC (Vasovist or MS-
325) (a partial list of chelates and their abbreviations are listed in
reference 1).
It is clear that Gd-chelate-based MR contrast agents have
allowed identification of pathologic tissue and physiological
processes that are not detectable by other non-invasive imaging
modalities. Dueto wide-spreadtissue and cell distribution, relatively
high doses(0.03–0.1 mmole/kg) of Gd
3+ in one of the above chelate
forms are essential to produce sufficient MR image definition.
However, available Gd-based contrast agents are eliminated
predominantly through the kidney. Administration of Gd-chelates
in patients with significantly reduced creatinine clearance or renal
impairment is linked to nephrogenic systemic fibrosis (NSF) [1].
Data suggest that NSF is associated with increased cell and tissue
exposure of Gd-chelates and Gd dissociation from chelates.
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safety warning [2].A Gd contrast agent that exhibits highercontrast
potency at a much lower Gd dose that is effective for use in renal
impaired subjects is urgently needed. Therefore, we explored the
possibility of using a biocompatible lipid nanoparticle with surface
bound Gd that can be retained in intact blood vasculature and can
be eliminated by the biliary route to avoid reliance on renal
function. This report describes our discovery of a high potency MR
contrast agent that is built on lipid-nanoparticles with Gd bound to
lipidic chelate, and its improved MRI contrast resolution and
elimination profile. This approach could address both imaging
sensitivity and safety of Gd use.
Results
Preparation and Characterization of Gd-lipid
Nanoparticles
First, we determined whether sequestration of Gd
3+ on the
surface of lipid nanoparticles through DTPA chelate embedded in
nanoparticle can enhance the MRI properties of Gd. To do so, we
constructed lipid nanoparticles containing phospholipids that
express Gd chelate or DTPA by incorporating DTPA-linked to
phosphatidylethanolamine or DTPA-PE into the lipid core of the
nanoparticles. The DTPA-PE was incorporated as 10% (m/m) of
lipid nanoparticles constructed with disteroylphosphatidylcholine.
Then Gd
3+ (as Gd
3+ in solution) was added to preformed lipid
nanoparticles (d=60–70 nm) expressing DTPA-PE (for binding to
Gd
3+ as Gd-DTPA-PE chelate). We found that at either 1:1 or 1:2
Gd-to-DTPA-PE molar ratio, all Gd
3+ added in solution was bound
to DTPA chelate molecules expressed on lipid nanoparticles
without significantly affecting the diameter of the nanoparticles
(Table 1). Complete association of Gd-to-DTPA-PE expressed on
lipid nanoparticles was verified based on the ability of free Gd
3+ to
quench calcein fluorescence (lex=490 nm; lem=520 nm). Results
indicated that no free Gd
3+ was available to quench calcein at both
1:1and 1:2Gd-to-DTPA-PEmole ratios.The completechelatingof
Gd to lipid-nanoparticle expressing DTPA was also verified by gel-
permeation chromatography (data not shown).
Next, to increase the bound water on the lipid nanoparticle
surface, we added 10 mole percentage of lipid conjugated to
methyl-polyethylene-glycol or mPEG-PE to lipid nanoparticles.
The molecular weight of mPEG-PE is varied to explore the role of
surface bound water on Gd paramagnetic properties. Paramag-
netic potency was evaluated as changes in T1 and T2, the
longitudinal and transverse relaxation time constants for MRI.
Compared to soluble Gd-DTPA or Gd-DTPA-BMA, we found
that inclusion of mPEG on Gd-lipid nanoparticle surfaces
significantly increased longitudinal T1 relaxivity, r1 (Table 1).
The Gd-lipid nanoparticles (Gd-LNP) containing mPEG2000-PE
exhibited the highest increase in r1, recorded at 134.8 mM
21*s
21.
This r1 value is about 33-fold higher than that of Gd-DTPA-
BMA (
r1=4mM
21*s
21), similar to the intrinsic value of Gd.
Based on these data, we selected lipid nanoparticles containing
mPEG2000-PE and Gd-DTPA-PE, referred to as Gd-LNP, for
subsequent experiments.
To evaluate effects of serum on Gd relaxivity, we first exposed
the Gd-LNP to 50% rat serum for 1 hr. All Gd-LNP, regardless of
the molecular weight of mPEG, as well as Gd-DTPA liposomes
exhibit 63–70 nm in diameters (Table 1). Gd-nanoparticle
diameters as determined by photon correlation spectroscopy, did
not exhibit any significant change in particle size due to serum
exposure. These particles were further evaluated for T1 relaxivity
with a 3T MRI instrument. Analysis of Gd concentration-
dependent relaxivity before and after serum exposure indicates
that molar relaxivity of Gd-LNP was not influenced by serum
(Figure 1). Morphology analysis of Gd-LNP by electron micros-
copy indicates distinct surface morphology compared to typical
liposomes expressing DTPA-PE (Figure 1B vs. 1C). The Gd-LNP
exhibited unique small electron exclusion bodies on lipid-
nanoparticle surfaces (Figure 1B) that were not seen with typical
lipid membrane vesicle or liposome preparations [3]. The
morphology reported for Gd-DTPA liposomes (Figure 1C) are
similar to those reported for PEG-expressed liposomes carrying
either Gd or gold [3,4]. This unique morphologic data is also
consistent with the much higher relaxivity data collected in Table 1
for mPEG2000-PE expressed Gd-LNP (Table 1 and Figure 1).
Table 1. Effects of varying the molecular weight of PEG expressed on Gd-lipid nanoparticles on Gd relaxivity constant and the
particle diameter.
Gd-DTPA-nanoparticles or
other formulations
a r1 [mM
21
*s
21]
b r2 [mM
21
*s
21]
b Diameter of particles (nm ± S.D.)
a
Nanoparticle with
mPEG5900 61.2 8.1 6360.2
mPEG2000 134.8 12.7 7060.6
mPEG750 21.8 3.9 6460.2
Gd-DTPA-liposomes 13.6 5.3 8860.4
Gd-DTPA-DPC Vasovist or MS 325 6.6 (28.0*) — Solution (*in rat serum)
Gd-DTPA Magnevist 3.8 2.4 Solution
Gd-DTPA-BMA Omniscan 4.0 3.1 Solution
aGd-DTPA lipid nanoparticles containing 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; 9 part), and 1,2- distearoyl-sn-Glycero-3-phophoethanolamine-N-DTPA
(DSPE-DTPA; 1 part), and N-(Carbonyl-methoxypolethyleneglycol-polymer of listed molecular weight)-1,2-distearoyl-sn-glycero-3-phospoethanolamine (mPEG-DSPE, 1
part) in suspension were mixed with gadolinium (III) chloride hexahydrate (Gd
3+, at 1:1 DTPA:Gd mole ratio) for 20 minutes. For comparison, water soluble commercial
agents such as Omniscan (Gd-DTPA-BMA) and Magnevist (GD-DTPA) were also included. The lipid particle diameter was expressed at mean 6a SD.
bThe relaxation time T1 was measured using the standard spin-echo sequence on a 3T MR scanner. These concentration dependent T1 values were plotted versus Gd
3+
concentration from which the rising curve was fitted by linear regression to estimate apparent molar relaxivity constant r1 and r2. The covariant of r1 and r2 data were
15% or lower.
doi:10.1371/journal.pone.0013082.t001
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Imaging in Rats
Subsequently, rats were administered with varying doses of the
Gd-LNP intravenously and T1 weighted MR images were
collected. At 15 minutes after 0.00125–0.02 mmole/kg Gd-LNP
administration, a dose much lower than the two clinically
approved agents Omniscan (Figure 2A) and Vasovist (Figure 2B),
all blood vasculature including vessels in the liver, heart, and
kidney were clearly apparent (Figure 2D–E). In contrast, at their
respective clinical doses, relatively low resolution of heart, liver
and some vasculature was noted with the FDA approved agents
(Figure 2A–B vs. 2C–E). More importantly, the FDA approved Gd
Figure 1. Effects of serum on Gd-concentration dependent change in longitudinal (T1) relaxation time and comparison of lipid-
nanoparticle morphology between Gd-DTPA liposome and Gd-lipid nanoparticles. Panel A: Gd-lipid nanoparticles containing mPEG2000-
PE (#,N) or Gd-DTPA liposomes without (mPEG) (e,X), were exposed to serum (N,X) and relaxation time was measured with a 3T MRI instrument as
described in Table 1. The data were fitted using linear regression. The electron micrographs represent morphology of Gd-lipid nanoparticles (panel B)
and Gd-DTPA liposomes (panel C). Samples were negatively stained with 1% phosphotunstate. Please note the small electron exclusion bodies
surrounding the Gd-lipid nanoparticles that were not detectable with Gd-DTPA liposomes. The bars in panels B and C represent 100 nm.
doi:10.1371/journal.pone.0013082.g001
Figure 2. Comparison of whole body MR image obtained using a 3T MR instrument. The rats were intravenously given indicated doses of
Gd, in Gd-DTPA-BMA (Omniscan, panel A), Gd-DTPA-DPC (Vasovist, panel B) or Gd-lipid nanoparticles (panels C-E). The mmole/kg dose of Gd were
0.05 for Omniscan (panel A), 0.03 for Vasovist (panel B), 0.00125, 0.01, 0.02 for Gd-lipid-nanoparticles (panels C, D & E, respectively). The DCE-MR
images were collected at 15 min post Gd administration. The circles and arrows indicate Gd-dependent MR contrast in the bladder and the heart
blood vessels. Also, the catheter line used for IV administration of Gd contrast is apparent as a high contrast line.
doi:10.1371/journal.pone.0013082.g002
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Gd in the rats administered Gd-LNP was detectable in MR images
(Figure 2). In rats administered with 0.01 mmole/kg Gd-LNP
(Figure 2D), the Gd dynamic-contrast enhanced (DCE) MRI
analysis revealed a signal-to-noise (S/N) ratio greater than 300 in
all vasculature (vasculature versus surrounding tissues). It provided
much greater anatomical and vascular details at 0.00125 than that
achieved with either 0.05 or 0.03 mmole/kg of Gd-DTPA-BMA
(Omniscan) or Gd-DTPA-DPC (Vasovist or MS-325) (Figure 2).
Thus, approximately 97% lower or only 3% of current clinical Gd
dose in Gd-LNP is needed to produce equivalent or higher MRI
contrast resolution.
We next evaluated the dose-response of Gd-LNP for MRI
contrast properties. As shown in Figure 2 panels C-E, a lower Gd
dose reduced contrast levels but provided better definition than that
collected at higher doses of Omniscan or Vasovist. Even at
0.00125 mmole/kg Gd-LNPdose,clear definition ofheartandliver
as well as vasculature connecting tissues was apparent. The MR
image collected at 0.00125 mmole/kg (or 1.25 mmole/kg) Gd-LNP
dose (Figure 2C) is about equivalent to that collected with
0.03 mmole/kg Gd in the Vasovist formulation, and better than
that collected with 0.05 mmole/kg Gd in the Omniscan formula-
tion. Thus, compared to 0.05 mmole/kg Gd dose in Omniscan,
only 2.5% [(0.00125/0.05)6100%] of Gd in Gd-LNP is needed to
produce higher quality MR images. The dose-response MR
contrast data were replicated with another batch of Gd-LNP to
verify these results. Collectively, based on the dose dependent data,
contrast potency improvement is estimated to be at least 24-fold
higher than Gd in the Vasovist formulation, which is considered the
most sensitive vascular agent approved for clinical use [5].
Kinetics and Clearance
While Gd-LNP are not cleared by the kidney or accumulated in
the bladder (Figure 2C–E), it is essential to define the route of Gd
elimination. To do so, we first performed a time course MR image
evaluation. The rat administered 0.01 mmole/kg Gd-LNP
produced high resolution images within 5 minutes in all
vasculature and highly perfused organs (Figure 3B). Gd-LNP
appeared concentrated within blood vasculature, even within the
kidney and liver (Figure 3C). By 15 minutes, Gd-LNP began to
appear in the gut and could be traced to the bile duct in the liver.
Furthermore, this process appeared complete within 24 hours,
suggesting Gd-LNP that lack any cell or tissue binding ligands on
their surface exhibited high intensity in blood without prolonged
tissue exposure (Figure 3D). This image data suggests that Gd
remains stably associated with DTPA-PE in lipid nanoparticles
such that they are subject to biliary, instead of renal elimination.
Should DTPA-PE in lipid nanoparticles metabolize to DTPA in
liver or blood vasculature, we might have detected Gd or Gd-
DTPA liberated from lipid nanoparticles as free form, appearing
as positive contrast images in the kidney and bladder, which did
not occur.
To further characterize the Gd clearance in Gd-LNP, we used
153Gd-labeled Gd-LNP in preliminary comparative pharmacoki-
netics and tissue distribution studies focusing on time-course blood
kinetics, major organ distribution, excretion and residual Gd in
muscle and skin tissues. As expected, rats (500 g; n=4/group)
administered with 0.05 mmole of Gd in LNP exhibited much
higher blood Gd concentrations than with the Gd-DTPA
formulation (Figure 4). The half-life of Gd-LNP and Gd-DTPA
in the blood is estimated to be 45.7 and 6.1 mins. Analysis of urine
and feces for Gd concentrations at 24 and 48 hrs revealed the
distinct differences between soluble Gd-DTPA and Gd-LNP. Rats
administered with Gd-DTPA almost exclusively eliminated Gd
through the renal route and Gd appeared in urine; while those
that received Gd-LNP eliminated Gd in feces through the biliary
route (Figure 5). It is interesting to note that much higher
concentrations of Gd excreted at both 24 and 48 hr post
Figure 3. Time course of Gd-enhanced MR images for Gd-lipid nanoparticles. The rats were administered intravenously with 0.01 mmole/kg
of Gd-lipid nanoparticles. The MR images at indicated time were collected with a 3T MR scanner. The animal was also scanned before dosing (panel A),
5 min (panel B), 15 min (panel C) or 24 hr (panelD) after Gd nanoparticle dosing. By 15 min (C), appearance of high positive contrast due to Gd
elimination into the bile which connects to the intestine (arrows) and the gut is apparent. Also by 24 hrs, all the Gd-lipid nanoparticles were eliminated
(panelD).Please note thatthe imagefor 24 hr did not line up due to different animal position. Thecontrast at 24 hr is found mainly in the GI tract,some
of which are contributed by fatty materials as well. Also, due to leakage at the site of Gd administration L at the left femoral vein, Gd localization is
apparent as a high contrast area. Please note the vaso-restriction # clearly apparent in panels B & C.
doi:10.1371/journal.pone.0013082.g003
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administered with Gd-LNP than those treated with Gd-DTPA
(Figure 5), suggesting that Gd-LNP may be more effective in
removing Gd from the body. These data confirmed the MRI data
in Figure 3.
At 48 hrs post-exposure, residual Gd was found in the lung,
liver and kidney for Gd-LNP; and for Gd-DTPA, most Gd was
found in the bladder. Analysis of skin and muscle tissues revealed
site-dependent highly variable skin and muscle accumulation in
rats administered with Gd-DTPA, and much less variable and
lower residual Gd concentrations were detected in rats adminis-
tered with Gd-LNP. We also performed a preliminary behavioral
toxicity study with mice and looked for skin agitation and lethargy
with increasing doses of Gd in the LNP formulation. We used
Magnevist and Omniscan for comparison. With as low as
0.02 mmole/kg Gd dose, mice began to exhibit skin agitation
within 15 min for Omniscan and began to show signs of lethargy
in 10–15 min. Gd given in Magnevist (Gd-DTPA) formulation
exhibited a lower degree of skin agitation and mice were not
lethargic with up to 0.2 mmole/kg dose. Under the same
conditions and with up to 0.4–0.6 mmole/kg Gd-LNP, mice did
not exhibit any signs of skin agitation. Collectively, these
preliminary data suggest that Gd remains stably associated with
LNP and thus no significant fraction of Gd is eliminated through
the renal route (which is the main route of Gd-DTPA elimination).
These data are also consistent with the MRI data presented in
Figures 2–3.
Discussion
Taking advantage of our ability to stably express Gd on the
LNP surface via DTPA-PE chelate, we have identified a Gd-LNP
formulation that exhibits about 33-fold higher r1 relaxivity than
the Gd-DTPA-BMA formulation. The high longitudinal r1
relaxivity exhibited by these lipid nanoparticles is within
experimental error of the maximum range predicted by simulation
of Bloembergen and Morgan theory for paramagnetic systems
[6,7]. The review by Woods et al [6] estimates the maximum Gd
r1 based on computer simulation for Gd to be 110–
120 mM
21*s
21. Single-wall carbon nanotubes (20–100 nm)
loaded with Gd were reported to exhibit 160–174 mM
21*s
21
[8]. However, the shape and composition of carbon nanotubes
may not be biocompatible.
The longitudinal relaxivity of Gd-LNP is also much higher than
other lipid nanoparticles (diameter: 213–247 nm) described by
Wickline and his colleagues (r1=12.7 mM
21*s
21) [9]. Their r1
values were much lower than observed with those coated with
mPEG2000 (Table 1). While others have explored DTPA-PE in
lipid vesicles or liposomes to enhance relaxivity of Gd-DTPA,
reported r1 values were around 10–12 mM
21*s
21 [4,10]. For this
Gd-lipid nanoparticle expressing mPEG2000-PE, the apparent high
relaxivity reported is more than 2.5-fold higher than those
achieved with Gd-DTPA-DPC (Vasovist) exposed to human
serum albumin. Serum albumin levels may depend on renal
disease state [11,12] under the most favorable conditions [13].
Much higher relaxivity was achieved with Gd-LNP expressing
mPEG2000-PE independent of serum albumin or other serum
proteins.
While the exact mechanisms leading to the observed improve-
ment in the longitudinal relaxivity remain elusive, it is possible that
the surface bound water on lipid nanoparticles through mPEG2000
greatly reduces molecular rotation. As schematically presented in
Figure 6, about 2–3 order of reduction in molecular rotation may
translate to 22–33-fold enhancement in relaxivity. This hypothesis
is consistent with the data presented in Table 1, where a change in
surface hydration and varying PEG polymer size provided
significantly different longitudinal relaxivity. Regardless, at the
Figure 4. Time-course blood Gd kinectics in rats. Rats were
intravenously given 0.5 mmole/kg of
125Gd either in Gd-lipid nanopar-
ticles (Gd-LNP) or soluble Gd-DTPA and Gd concentrations in blood
were analyzed and presented as mmole/ml. Data presented were mean
6a S.D of n=4 per treatment group. * Indicates p,0.05 by student T
test.
doi:10.1371/journal.pone.0013082.g004
Figure 5. Comparison of Gd in LNP (hatched) vs soluble Gd-
DTPA (filled) formulation excreted in feces and urine at 24 and
48 hrs. Rats were intravenously given 0.5 mmole/kg of
125Gd either in
Gd-lipid nanoparticles (Gd-LNP) or soluble Gd-DTPA. The urine and
feces collected from rats housed in metabolic cages were analyzed at
24 and 48 hr. Data were expressed as mean 6a S.D. in mmole/g [Gd] for
each treatment group. * Indicates p,0.05 by student T test.
doi:10.1371/journal.pone.0013082.g005
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dramatically improved longitudinal relaxivity and also retained a
majority of Gd in vasculature under normal conditions. A
combination of reduced cellular and tissue uptake and enhanced
longitudinal relaxivity likely contributed to the overall improve-
ments in contrast potency (Figure 6). These and other mechanisms
remain to be evaluated.
It is important to emphasize that Gd-contrast is almost
completely eliminated by 24 hours, and that most of the Gd-
LNP contrast was detected in the gut. In prior studies of liposomes
expressing PEG, there is significant uptake and retention of PEG-
liposomes in Kupffer cells in the liver and macrophages, and at
least 20% of the injected dose remained in the liver at or beyond
50 hours in mice [3]. While detailed tissue localization studies are
planned, the image data suggests that no significant Gd-LNP were
detectable in the spleen or the liver by 24 hours (Figure 3). The
distinct in vivo disposition profile between traditional liposome
formulations and the Gd-LNP composition described here is also
consistent with the unique morphology of Gd-LNP detected by
electron microscopy (Figure 1B–C). While it needs to be validated,
the current Gd-LNP with diameter ,70 nm is far greater than the
50–70 kDa (d,3–4 nm) renal filtration threshold for globular
proteins in humans. As retention of free or chelated Gd molecules
in the kidney and tissues are proposed as one of the root causes of
NSF in patients with renal diseases or impairment, the Gd-LNP
hold promise both to improve effectiveness of contrast enhanced
MRI as well as safety of Gd use in this patient population.
More importantly, a more complete clearance of these lipid-
nanoparticles also suggests that background non-specific exposure
or accumulation of these lipid-nanoparticle carriers in tissues is
low. Thus, by attaching targeting molecules or peptides, these lipid
nanoparticles could provide high specificity and low off-target
accumulation for targeting to tumor receptors accessible through
blood, i.e. leaky tumor-associated vasculature. Given the low
degree of non-specific tissue accumulation, targeted lipid nano-
particles could be developed further as a better molecular imaging
agent and drug loaded targeted nanoparticles could provide much
higher therapeutic indices than classical liposomes or nanoparticles
using other matrices.
The specific application of the Gd-lipid nanoparticles as a
contrast agent remains to be directly demonstrated. However, it is
likely that with a 45 min, instead of 5 min half-life, it could be used
in a single dose instead of up to three injections to provide whole
body MRI scans for detecting atherosclerosis. In addition, with the
high resolution and low dose needed to detect vasculature in detail,
it is likely to provide early detection of pathogenic conditions in
highly perfused organs such as the lung, liver, kidney and
microhemorrhage in the brain. Due to its movements, a different
MR sequence may be needed for MR imaging of the lung. These
and other potential applications are beyond the scope of this
report and are under our current investigation.
In this report, we employed a linear chelate DTPA for proof-of-
concept studies. The macrocyclic chelate DOTA can extend the
DTPA, as a linear chelate, binding affinity of Gd about 3–4 orders
of magnitude. The increased binding affinity of macrocyclic
chelate to Gd has been proposed as one of the mechanisms to
reduce clinical toxicity due to release of free Gd into cells and
tissues. It is conceivable that we can further extend the DTPA in
our Gd-LNP using macrocyclic chelating agents such as DOPA-
PE, instead of DTPA-PE. These and other approaches to further
stabilize the Gd association to the Gd-LNP are currently under
our investigation. Regardless, the current formulation of Gd-LNP
appeared to reduce non-specific tissue uptake and provided
improvement in the extent of efficient elimination from the body.
In summary, our results indicate that an approximate 22–33-
fold lower dose of current Gd contrast agents could be used to
achieve similar or better whole-body image resolution for medical
diagnosis. The enhancement in contrast potency achieved with
Gd-LNP enable the use of only 3% or less of current clinical Gd
dose needed for MRI procedures with potentially better vascular
imaging capabilities. Furthermore, the rapid onset and unique
clearance properties of Gd-LNP could also be adapted for system
biology profiling of in vivo drug target distribution for new
molecules that are identified as part of global/international efforts
in pharmacogenomic and drug/target discovery research.
Materials and Methods
Materials
Phospholipids,1,2-distearoyl-sn-glycero-3-phosphocholine(DSPC)
and 1,2- distearoyl-sn-Glycero-3-phophoethanolamine-N-DTPA
(DTPA-PE) were purchased from Avanti Polar Lipids (Alabaster,
AL). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly
(ethylene glycol)MW] (mPEG-DSPE) was obtained from Genzyme
Pharmaceuticals (Cambridge, MA). Gadolinium (III) chloride
hexahydrate (Gd
3+) and calcein were purchased from Sigma
Chemical Co. (St. Louis, MO). Clinical Gd contrast agents were
purchased from clinical pharmacy. Other ingredients were of
analytical grade or higher.
Preparation and characterization of Gd-lipid
nanoparticles
The Gd-DTPA lipid nanoparticles were prepared by mixing
DSPC:DTPAPE:mPEG-DSPE (9:1:1 mole ratio), were dissolved
in chloroform, dried into a thin film under N2 and placed in a
vacuum overnight. The same lipid composition without mPEG-PE
were prepared as Gd-DTPA-liposomes. The phosphate buffered
saline (PBS, pH 7.4) was added to the film and either sonicated or
extruded through 50 nm polycarbonic filter at 60uC. To prepare
Gd bound to lipid nanoparticles, the nanoparticles in suspension
Figure 6. Schematic presentation of soluble and lipid nano-
particle associated Gd-DTPA molecular rotation and impact on
relaxivity as well as their retention in healthy blood vascula-
ture. The medium circular Gd and small circular DTPA chelate in
solution or H2O exhibit high molecular rotation (,10
10 sec
21) that
influences water proton relaxation, which typically produce 4–
6m M
21*sec
21 relaxivity. When Gd-DTPA is bound to lipid nanoparticle
surface with surface bound water molecules attracted by PEG and Gd’s
molecular rotation is reduced to ,10
7–8 sec
21, relaxivity is greatly
increased to about ,130 mM
21*sec
21 (not drawn to scale). Gd in Gd-
LNP also reduces the cellular uptake and thus lowers the cellular and
tissue accumulation in non-pathogenic tissues and cells which may
relate to clinical presentation of fibrosis.
doi:10.1371/journal.pone.0013082.g006
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3+ (1:1 DTPA-PE:Gd mole ratio) for 20
minutes. The same method was used to prepare
153Gd labeled
Gd-lipid nanoparticles where Gd
3+ was replaced with
153Gd
3+. For
comparison, water soluble commercial agents such as Gd-DTPA-
BMA and Gd-DTPA were also included. The lipid particle
diameter was determined with a Malvern Zetasizer 5000 photon
correlation spectroscopy (Malvern Instruments, PA), and expressed
at mean 6a SD.
Magnetic Resonance Measurements
In vitro measurements. The relaxation time T1 was
measured using the standard spin-echo sequence on a 3T MR
scanner with a volume head coil as RF receiver operating at 37uC.
For T1 measurements, TE (echo time) was fixed to 9 ms and seven
TR (repetition time) were 133, 200, 300, 500, 750, 1000 and
2000 ms, respectively. For T2 measurements, TR was fixed to
2000 ms and four TE were 15, 30, 45, and 60 ms, respectively.
The imaging intensities were fitted to obtain the corresponding T1
and T2 values for each concentration of Gd. These concentration
dependent T1 values were plotted versus Gd
3+ concentration from
which the rising curve was fitted by linear regression to estimate
apparent molar relaxivity constant r1 and r2. The covariant of r1
and r2 data were 15% or lower.
In vivo rat imaging studies. All animal experiments were
performed with approved protocol # 2372-05 from the University
of Washington Institutional Animal Care and Use Committee.
Rats under anesthesia were implanted with an intravenous
catheter in the femoral vein. They were given indicated doses of
Gd-chelate or Gd-lipid nanoparticle preparations in 0.4 ml. MR
images were collected sequentially at indicated time points with a
3T MR scanner (Acheiva, Philips Medical Systems, Best,
Netherlands) using a small quadrature birdcage radiofrequency
receiver coil. Axial, 2D T1-weighted, turbo spin-echo of the whole
body was performed of each rat (TR/TE =750/6.4 ms, TSE
factor 2, 5006470 mm in-plane resolution, 2-mm contiguous slice
thickness). In addition, coronal 3D RF-spoiled, fat suppressed,
gradient echo images were acquired (TR/TE/Flip =19/1.55 ms/
40 degrees, in-plane voxel size =550650 mm, 1.2 mm slice
thickness). A control marker of Omniscan doped water was
included in the imaging field of view to normalize signal intensity
of each set of images across animals.
Statistical Analysis
Data are presented as the mean 6 SD. Statistical significance
was evaluated either by unpaired Student’s t-tests (two-sided) or
one way ANOVA using SigmaPlot software (Systat, San Jose, CA).
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